Cel-Sci (NYSEAMERICAN:CVM) Trading 6.9% Higher – Still a Buy?

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s share price was up 6.9% during mid-day trading on Wednesday . The stock traded as high as $3.60 and last traded at $3.43. Approximately 52,583 shares traded hands during mid-day trading, an increase of 56% from the average daily volume of 33,663 shares. The stock had previously closed at $3.21.

Cel-Sci Stock Performance

The firm has a market capitalization of $29.36 million, a PE ratio of -0.36 and a beta of 0.99. The stock’s 50-day moving average price is $4.38 and its 200 day moving average price is $6.23. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.39 and a quick ratio of 1.35.

Cel-Sci (NYSEAMERICAN:CVM) last announced its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.76) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Cel-Sci Corporation will post -0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Cel-Sci

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after buying an additional 109,352 shares during the period. Geode Capital Management LLC grew its holdings in Cel-Sci by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after acquiring an additional 18,432 shares in the last quarter. MAI Capital Management increased its position in Cel-Sci by 18.4% during the 3rd quarter. MAI Capital Management now owns 76,861 shares of the company’s stock valued at $707,000 after purchasing an additional 11,928 shares during the period. Bank of America Corp DE increased its position in Cel-Sci by 2,188.2% during the 2nd quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after purchasing an additional 39,190 shares during the period. Finally, State Street Corp raised its holdings in shares of Cel-Sci by 9.9% in the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after purchasing an additional 2,300 shares in the last quarter. Institutional investors own 12.08% of the company’s stock.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.